Phase II, randomized, multicenter, double-blind, placebo-controlled trial of a polyclonal anti-Staphylococcus aureus capsular polysaccharide immune globulin in treatment of Staphylococcus aureus bacteremia

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 12, 2007, Pages 4249-4254

  Rupp, Mark E ^a,h   Holley Jr , H Preston ^b   Lutz, Jon ^c   Dicpinigaitis, Peter V ^d   Woods, Christopher W ^e,g   Levine, Donald P ^f   Veney, Naomi ^b   Fowler Jr , Vance G ^g  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b Nabi Biopharmaceuticals   (United States)

^c Saint Agnes Medical Center   (United States)

^d MONTEFIORE MEDICAL CENTER   (United States)

^e DURHAM VA MEDICAL CENTER   (United States)

^f WAYNE STATE UNIVERSITY   (United States)

^g DUKE UNIVERSITY MEDICAL CENTER   (United States)

^h UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTASTAPH; ANTIINFECTIVE AGENT; PLACEBO; POLYSACCHARIDE IMMUNE GLOBULIN; UNCLASSIFIED DRUG; VANCOMYCIN;

ADULT; ANTIBACTERIAL ACTIVITY; ARTICLE; BACKACHE; BACTEREMIA; CHEST TIGHTNESS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DYSPNEA; FEMALE; FEVER; HOSPITALIZATION; HUMAN; INJECTION SITE EDEMA; MALE; MULTICENTER STUDY; NAUSEA; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RIGOR; STAPHYLOCOCCUS AUREUS; TACHYCARDIA; VOMITING; WHEEZING;

ADULT; AGED; BACTEREMIA; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYPOKALEMIA; IMMUNOGLOBULINS; INFUSIONS, INTRAVENOUS; LENGTH OF STAY; MALE; MIDDLE AGED; PLACEBOS; POLYSACCHARIDES, BACTERIAL; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TACHYCARDIA;

EID: 36749082119     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00570-07     Document Type: Article

References (27)

1. Arbeit, R. D., W. W. Karakawa, W. W. Vann, and J. B. Robins. 1984. Predominance of two newly described capsular polysaccharide types among clinical isolates of Staphylococcus aureus. Diagn. Microbiol. Infect. Dis. 2:85-91.
2. Benjamin, D. K., R. Schelonka, R. White, H. P. Holley, Jr., E. Bifano, J. Cummings, K. Adcock, D. Kaufman, B. Puppala, P. Riedel, B. Hall, J. White, and C. M. Cotton. 2006. A blinded, randomized, multicenter study of an intravenous Staphylococcus aureus immune globulin. J. Perinatol. 26:290-295.
3. Centers for Disease control and Prevention. 2004. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004. Am. J. Infect. Control 32:470-485.
4. Chang, F. Y., B. B. MacDonald, and J. F. Peacock. 2003. A prospective multicenter study of Staphylococcus aureus bacteremia: incidence of endocarditis, risk factors for mortality, and clinical impart of methicillin resistance. Medicine 82:322-332.
5. Chang, S., D. M. Sievert, J. C. Hageman, M. L. Boulton, F. C. Tenover, F. P. Downes, S. Shah, J. T. Rudrik, G. R. Pupp, W. J. Brown, D. Cardo, and S. K. Fridkin. 2003. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N. Engl. J. Med. 348:1342-1347.
6. Cowden, J., and S. K. Parker. 2006. Intravenous immunoglobulin: production, uses and side effects. Pediatr. Infect. Dis. J. 25:641-642.
7. Fattom, A., J. Sarwar, A. Ortiz, and R. Naso. 1996. A Staphylococcus aureus capsular polysaccharide (CP) vaccine and CP-specific antibodies protect mice against bacterial challenge. Infect. Immun. 64:1659-1665.
8. Fattom, A., R. Schneerson, S. C. Szu, W. F. Vann, J. Shiloach, W. W. Karakawa, and J. B. Robbins. 1990. Synthesis and immunologic properties in mice of vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides conjugated to Pseudomonas aeruginosa exotoxin A. Infect. Immun. 58:2367-2374.
9. Fowler, V. G., H. W. Boucher, R. G. Corey, E. Abrutyn, A. W. Karchmer, M. E. Rupp, D. P. Levine, H. F. Chambers, F. P. Tally, G. A. Vigliani, C. H. Cabell, A. S. Link, I. DeMeyer, S. G. Filler, M. Zervos, P. Cook, J. Parsonnet, J. M. Berstein, C. S. Price, G. N. Forrest, G. Fatkenheur, M. Gareca, S. J. Rehm, H. R. Brodt, A. Tice, and S. E. Cosgrove. 2006. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N. Engl. J. Med. 355:653-665.
10. Fowler, V. G., M. K. Olsen, R. Corey, C. W. Woods, C. H. Cabell, L. B. Reller, A. C. Cheng, T. Dudley, and E. Z. Oddone. 2003. Clinical identifiers of complicated Staphylococcus aureus bacteremia. Arch. Intern. Med. 163:2066-2072.
11. Karakawa, W., A. Sutton, R. Schneerson, A. Karpas, and W. Vann. 1988. Capsular antibodies induce type-specific phagocytosis of capsulated Staphylococcus aureus by human polymorphonuclear leukocytes. Infect. Immun. 561:1090-1095.
12. Kelly, J. 2000. Immunotherapy against antibiotic resistant bacteria: the Russian experience with an antistaphylococcal hyperimmune plasma and immunoglobulin. Microbes Infect. 2:1383-1392.
13. Krotova, T., M. Gerasimova, O. Koloshtivina, V. Kozlova, and V. Kuzmin. 1975. Use of antistaphylococcal polyglobulin and antistaphylococcal plasma in children with various staphylococcal diseases. Prob. Gematol. Pereliv. Krovi. 20:28-31.
14. Kuehnert, M. J., H. A. Hill, B. A. Kupronis, J. I. Tokars, S. L. Solomon, and D. B. Jernigan. 2005. Methicillin-resistant Staphylococcus aureus hospitalizations, United States. Emerg. Infect. Dis. 11:868-872.
15. Lee, J., J. Park, S. Shephard, V. Carey, and A. Fattom. 1997. Protective efficacy of antibodies to the Staphylococcus aureus type 5 capsular polysaccharide in a modified model of endocarditis in rats. Infect. Immun. 65:4146-4151.
16. Mangili, A., I. Bica, D. R. Snydman, and D. H. Hamer. 2005. Daptomycin-resistant, methicillin-resistant Staphylococcus aureus. Clin. Infect. Dis. 40: 1058-1060.
17. Noskin, G. A., R. J. Rubin, J. J. Schentag, J. Kluytmans, F. C. Hedblom, M. Smulders, E. Lapetine, and F. Gemmen. 2005. The burden of Staphylococcus aureus infections on hospitals in the United States. Arch. Intern. Med. 165:1756-1761.
18. O'Riordan, K., and J. C. Lee. 2004. Staphylococcal aureus capsular polysaccharides. Clin. Microbiol. Rev. 17:218-234.
19. Pillai, S. K., G. Sakoulas, C. Wennersten, G. M. Eliopoulos, R. C. Moellering, M. J. Ferraro, and H. S. Gold. 2002. Linezolid resistance in Staphylococcus aureus: characterization and stability of resistant phenotype. J. Infect. Dis. 186:1603-1607.
20. Rathjen, T. E. 2005. Nabi Biopharmaceuticals announces results of StaphVAX confirmatory phase III clinical trial. http://phx.corporate-ir.net/ phoenix.zhtml. Released 1 November 2005.
21. Rubin, R. J., C. A. Harrington, A. Poon, K. Dietrich, J. A. Greene, and A. Moiduddin. 1999. The economic impact of Staphylococcus aureus infection in New York City hospitals. Emerg. Infect. Dis. 5:9-17.
22. Rupp, M. E., J. Lutz, P. Dicpinigaitis, C. W. Woods, D. Levine, H. P. Holley, Jr., and the Altastaph Study Group. 2005. Trial of Staphylococcus aureus capsular polysaccharide (CPS) immune globulin in subjects with S. aureus bacteramia and persistent fever, abstr. LB-6, p. 52. Abstr. 43rd Ann. Meet. IDSA, San Francisco, CA, 6 to 9 October 2005.
23. Shapiro, S. S., and M. B. Wilk. 1965. An analysis of variance test for normality. Biometrika 52:591-599.
24. Shinefield, H., S. Black, A. Fattom, G. Horwith, S. Rasgon, J. Ordonez, H. Yeoh, D. Law, B. Robbins, R. Schneerson, L. Muenz, and R. Naso. 2002. Use of a Staphylococcal aureus conjugate vaccine in patients receiving hemodialysis. N. Engl. J. Med. 346:491-496.
25. Steinberg, J. P., C. C. Clark, and B. O. Hackman. 1996. Nosocomial and community-acquired Staphylococcus aureus bacteremia from 1980 to 1993: impact of intravascular devices and methicillin resistance. Clin. Infect. Dis. 23:256-259.
26. Weems, J. J., Jr., J. P. Steinberg, S. Filler, J. W. Baddley, G. R. Corey, P. Sampathkumar, L Winston, J. F. John, C. J. Kubin, R. Talwani, T. Moore, J. M. Patti, S. Hetherington, M. Texter, E. Wenzel, V. A. Kelley, and V. G. Fowler, Jr. 2006. Phase II, randomized, double-blind, multicenter study comparing the safety and pharmacokinetics of tefibazumab to placebo for treatment of Staphylococcus aureus bacteremia. Antimicrob. Agents Chemother. 50:2751-2755.
27. Wisplinghoff, H., T. Bischoff, S. M. Tallent, H. Seifert, R. P. Wenzel, and M. B. Edmond. 2004. Nosocomial bloodstream infection in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis. 39:309-317.